|
|
Article: Rhone-Poulenc Rorer Files NDA For CFC-Free Allergic Rhinitis Nasal Spray
- Article from:
- PR Newswire
- Article date:
- January 9, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
COLLEGEVILLE, Pa., Jan. 9 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) announced today that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for Nasacort(R) HFA (triamcinolone acetonide) Nasal Inhaler, a non-chlorofluorocarbon (CFC) nasal spray for the treatment of seasonal and perennial allergic rhinitis symptoms in adults and children six years of age and older.
RPR developed Nasacort HFA -- a reformulation of the currently marketed Nasacort(R) (triamcinolone acetonide) Nasal Inhaler -- in response to an international agreement known as the Montreal Protocol, which calls for the phase-out of products ...